METTL3 in cancer-associated fibroblasts-derived exosomes promotes the proliferation and metastasis and suppresses ferroptosis in colorectal cancer by eliciting ACSL3 m6A modification

• Published in: Biology direct Vol. 19; no. 1; pp. 68 - 13
• Main Authors: Ren, Hongtao, Wang, Mincong, Ma, Xiulong, An, Lei, Guo, Yuyan, Ma, Hongbing
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.08.2024; BioMed Central; BMC
• Subjects: Adenosine; Animal models; Animals; Assaying; Biotechnology; Breast cancer; CAFs; Cancer; Cancer-Associated Fibroblasts - metabolism; Cell culture; Cell death; Cell Line, Tumor; Cell Proliferation; Cell viability; Coenzyme A Ligases - genetics; Coenzyme A Ligases - metabolism; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; CRC; Exosomes; Exosomes - genetics; Exosomes - metabolism; Ferroptosis; Ferroptosis - genetics; Fibroblasts; Genetic aspects; Glutathione; Health aspects; Humans; Immunoprecipitation; In vivo methods and tests; Ligases; m6A; Male; Medical prognosis; Metastases; Metastasis; Methyltransferases; Methyltransferases - genetics; Methyltransferases - metabolism; METTL3; Mice; Mice, Nude; Molecular biology; N6-methyladenosine; Neoplasm Metastasis; Particles; Physiological aspects; Post-translational modification; Reactive oxygen species; RNA modification; Tumorigenesis; Ultracentrifugation; Western blotting; Wound healing; China; United States > US; CAFs; CRC; METTL3; Ferroptosis; m6A; ACSL3; Exosomes
• ISSN: 1745-6150; 1745-6150
• DOI: 10.1186/s13062-024-00511-z

Cancer-associated fibroblasts (CAFs) have been reported that can affect cancer cell proliferation, metastasis, ferroptosis, and immune escape. METTL3-mediated N6-methyladenine (m6A) modification is involved in the tumorigenesis of colorectal cancer (CRC). Herein, we investigated whether METTL3-dependent m6A in CAFs-derived exosomes (exo) affected CRC progression. qRT-PCR and western blotting analyses detected levels of mRNAs and proteins. Cell proliferation and metastasis were evaluated using MTT, colony formation, transwell, and wound healing assays, respectively. Cell ferroptosis was assessed by detecting cell viability and the levels of Fe+, reactive oxygen species, and glutathione after erastin treatment. Exosomes were isolated from CAFs by ultracentrifugation. The m6A modification profile was determined by methylated RNA immunoprecipitation assay and the interaction between METTL3 and ACSL3 (acyl-CoA synthetase 3) was verified using dual-luciferase reporter assay. Animal models were established for in vivo analysis. CAFs promoted CRC cell proliferation and metastasis, and suppressed cell ferroptosis. METTL3 was enriched in CAFs and was packaged into exosomes. The m6A modification and METTL3 expression were increased in CRC samples. Knockdown of METTL3 in CAFs-exo suppressed CRC cell proliferation and metastasis, and induced cell ferroptosis. Mechanistically, METTL3 induced ACSL3 m6A modification and stabilized its expression. The anticancer effects mediated by METTL3-silenced CAFs-exo could be rescued by ACSL3 overexpression. Moreover, in vivo assay also showed that CAFs-exo with decreased METTL3 could hinder CRC growth and metastasis in mice models. CAFs promoted the proliferation and metastasis, and restrained the ferroptosis in CRC by exosomal METTL3-elicited ACSL3 m6A modification.